Patent US2391715A successfully refreshed from Google Patents.
Patent US4664650A successfully refreshed from Google Patents.
US4664650A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Apparatus for parenteral infusion of fluid containing beneficial agent
Assignee: Alza Corp
•
Filing: 1983-10-31
•
Granted: 1987-05-12
•
Expires: 2003-10-31
Abstract
Abstract A parenteral delivery system is disclosed for administering a beneficial agent to a recipient. The system comprises (a) a primary container of a medical fluid; (b) a primary drip chamber in fluid communication with the primary container; (c) a primary formulation chamber in fluid communication with the primary drip chamber and housing an agent dispensing device or a beneficial agent; (d) a secondary container of a medical fluid; (e) a secondary drip chamber in fluid communication with the secondary container; (f) a secondary formulation chamber in fluid communication with the secondary drip chamber and housing an agent dispensing device or a beneficial agent; and (g) a common tubing in communication with the primary formulation chamber and the secondary formulation chamber for communicating the system with the recipient.
Inventors
- 👤 John Urquhart
- 👤 Felix Theeuwes
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 21:07
CPC Classifications
A; A61; A61M; A61M5/00; A61M5/14; A61M5/1407; A61M5/142; A61M5/145; A61M2005/14513
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
282 words
A parenteral delivery system for administering a beneficial agent formulation to an animal, the system comprising: (a) a primary path for the flow of a parenterally acceptable fluid therethrough; (b) a formulation chamber in the primary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the primary path into the formulation chamber; (3) an osmotic delivery device in the formulation chamber, the osmotic device comprising: (a) a wall formed of a semipermeable material that surrounds and forms; (b) an osmotic compartment; (c) an agent formulation in the osmotic compartment that exhibits an osmotic pressure gradient across the semipermeable wall against fluid present in the formulation chamber; (4) an outlet for letting an agent formulation leave the formulation chamber; (c) a secondary path for the flow of a parenterally acceptable fluid therethrough; (d) a formulation chamber in the secondary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the secondary path into the formulation chamber; (3) an osmotic delivery device in the formulation chamber, the osmotic device comprising: (a) a wall formed of a semipermeable material that surrounds and forms; (b) an osmotic compartment; (c) an agent formulation in the osmotic compartment that exhibits an osmotic pressure gradient across the semipermeable wall against fluid when present in the formulation chamber; (4) an outlet for letting an agent formulation leave the formulation chamber; and, (e) a common path in communication with the primary path and in communication with the secondary path for receiving agent formulation, which common path when the system is in use is in communication with the animal for administering beneficial agent formulation thereto.
Claim 2
Dependent Claim
282 words
A parenteral delivery system for administering a beneficial agent formulation to an animal, the system comprising: (a) a primary path for the flow of a parenterally acceptable fluid therethrough; (b) a formulation chamber in the primary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the primary path into the formulation chamber; (3) an osmotic delivery device in the formulation chamber, the osmotic device comprising: (a) a wall formed of a semipermeable material that surrounds and forms; (b) an osmotic compartment; (c) an agent formulation in the osmotic compartment that exhibits an osmotic pressure gradient across the semipermeable wall against fluid present in the formulation chamber; (4) an outlet for letting an agent formulation leave the formulation chamber; (c) a secondary path for the flow of a parenterally acceptable fluid therethrough; (d) a formulation chamber in the secondary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the secondary path into the formulation chamber; (3) an osmotic delivery device in the formulation chamber, the osmotic device comprising: (a) a wall formed of a semipermeable material that surrounds and forms; (b) an osmotic compartment; (c) an agent formulation in the osmotic compartment that exhibits an osmotic pressure gradient across the semipermeable wall against fluid when present in the formulation chamber; (4) an outlet for letting an agent formulation leave the formulation chamber; and, (e) a common path in communication with the primary path and in communication with the secondary path for receiving agent formulation, which common path when the system is in use is in communication with the animal for administering beneficial agent formulation thereto.
Claim 3
Dependent Claim
255 words
A parenteral delivery system for administering a beneficial agent formulation to an animal, the system comprising: (a) a primary path for the flow of a parenterally acceptable fluid therethrough; (b) a formulation chamber in the primary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the primary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising a matrix formed of a polymeric composition permeable to the passage of a beneficial agent by diffusion, and an effective amount of a beneficial agent in the matrix; (4) an outlet for letting an agent formulation leave the formulation chamber; (c) a secondary path for the flow of a parenterally acceptable fluid therethrough; (d) a formulation chamber in the secondary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the secondary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising a matrix formed of a polymeric composition permeable to the passage of a beneficial agent by diffusion, and an effective amount of a beneficial agent in the matrix; (4) an outlet for letting an agent formulation leave the formulation chamber; and, (e) a common path in communication with the primary path and in communication with the secondary path for receiving agent formulation, which common path when the system is in use is in communication with the animal for administering beneficial agent formulation thereto.
Claim 4
Dependent Claim
255 words
A parenteral delivery system for administering a beneficial agent formulation to an animal, the system comprising: (a) a primary path for the flow of a parenterally acceptable fluid therethrough; (b) a formulation chamber in the primary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the primary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising a matrix formed of a polymeric composition permeable to the passage of a beneficial agent by diffusion, and an effective amount of a beneficial agent in the matrix; (4) an outlet for letting an agent formulation leave the formulation chamber; (c) a secondary path for the flow of a parenterally acceptable fluid therethrough; (d) a formulation chamber in the secondary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the secondary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising a matrix formed of a polymeric composition permeable to the passage of a beneficial agent by diffusion, and an effective amount of a beneficial agent in the matrix; (4) an outlet for letting an agent formulation leave the formulation chamber; and, (e) a common path in communication with the primary path and in communication with the secondary path for receiving agent formulation, which common path when the system is in use is in communication with the animal for administering beneficial agent formulation thereto.
Claim 5
Dependent Claim
285 words
A parenteral delivery system for administering a beneficial agent formulation to an animal, the system comprising: (a) a primary path for the flow of a parenterally acceptable fluid therethrough; (b) a formulation chamber in the primary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the primary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising; depots of beneficial agent dispersed in and substantially individually surrounded by a polymer permeable to the passage of fluid and impermeable to the passage of agent, said agent released by forming apertures by hydrostatic pressure to release the agent at a controlled rate; (4) an outlet for letting an agent formulation leave the formulation chamber; (c) a secondary path for the flow of a parenterally acceptable fluid therethrough; (d) a formulation chamber in the secondary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the secondary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising; depots of beneficial agent dispersed in and substantially individually surrounded by a polymer permeable to the passage of fluid and impermeable to the passage of agent, said agent released by forming apertures by hydrostatic pressure to release the agent at a controlled rate; (4) an outlet for letting an agent formulation leave the formulation chamber; and, (e) a common path in communication with the primary path and in communication with the secondary path for receiving agent formulation, which common path when the system is in use is in communication with the animal for administering beneficial agent formulation thereto.
Claim 6
Dependent Claim
285 words
A parenteral delivery system for administering a beneficial agent formulation to an animal, the system comprising: (a) a primary path for the flow of a parenterally acceptable fluid therethrough; (b) a formulation chamber in the primary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the primary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising; depots of beneficial agent dispersed in and substantially individually surrounded by a polymer permeable to the passage of fluid and impermeable to the passage of agent, said agent released by forming apertures by hydrostatic pressure to release the agent at a controlled rate; (4) an outlet for letting an agent formulation leave the formulation chamber; (c) a secondary path for the flow of a parenterally acceptable fluid therethrough; (d) a formulation chamber in the secondary path, the formulation chamber comprising: (1) a wall surrounding a lumen; (2) an inlet for letting fluid from the secondary path into the formulation chamber; (3) an agent delivery device in the formulation chamber, the delivery device comprising; depots of beneficial agent dispersed in and substantially individually surrounded by a polymer permeable to the passage of fluid and impermeable to the passage of agent, said agent released by forming apertures by hydrostatic pressure to release the agent at a controlled rate; (4) an outlet for letting an agent formulation leave the formulation chamber; and, (e) a common path in communication with the primary path and in communication with the secondary path for receiving agent formulation, which common path when the system is in use is in communication with the animal for administering beneficial agent formulation thereto.
References Cited (Backward Citations)
US1654745A
Cited
US2254994A
Cited
US2954028A
Cited
US2849256A
Cited
US3305446A
Cited
CH497181A
Cited
US3797494A
Cited
US3854480A
Cited
US3993073A
Cited
US3995631A
Cited
US3756237A
Cited
US3760984A
Cited
US3948254A
Cited
US3845770A
Cited
US3921636A
Cited
US4177256A
Cited
US3941126A
Cited
US3993072A
Cited
US3993066A
Cited
US4203439A
Cited
US4217894A
Cited
US4233973A
Cited
US4325368A
Cited
US4219022A
Cited
US4256105A
Cited
US4256104A
Cited
US4320759A
Cited
US4465471A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1990-05-11 | 1990-11-10 | 1991-05-12 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1994-05-11 | 1994-11-10 | 1995-05-12 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1998-05-11 | 1998-11-10 | 1999-05-12 | $7700.00 | Window Closed / Lapsed |